Home
Search
Search Results
Previously Searched
3121 results found
Expand All
Apply All
3121 results found

BIO Applauds MLP Parity Act, Thanks Senate and House Sponsors
Press Release  •  October 25, 2017
The bipartisan Master Limited Partnerships Parity Act of 2017 would level the playing field in the tax code by giving investors in renewable energy projects access to a decades-old corporate structure with a tax advantage now available only to fossil fuel projects.
Read More

BIO, Member Companies Ask Congress to Reauthorize Section 9003 Program in Farm Bill
Press Release  •  October 19, 2017
BIO and 66 renewable chemical producers today asked leaders of the House and Senate Committees on Agriculture to reauthorize the Farm Bill’s Biorefinery, Renewable Chemical, and Biobased Manufacturing Assistance Program (Section 9003) and “fully and unconditionally allow renewable chemical standalone manufacturing facilities” to receive Section 9003 Program loan guarantees without requiring production of advanced biofuels.
Read More

BIO Applauds Senate Introduction of Renewable Chemicals Tax Credit
Press Release  •  October 19, 2017
BIO thanks Sen. Debbie Stabenow (D-MI) and co-sponsors Sens. Tammy Baldwin (D-WI), Susan Collins (R-ME), Chris Coons (D-DE), and Al Franken (D-MN) for introducing the Renewable Chemicals Act of 2017 (S.1980), which would create a targeted, short-term tax credit for production of qualifying renewable chemicals or investment in production facilities.
Read More

BIO Investor Forum Concludes
Business Development, BIO One-on-One Partnering  •  Press Release  •  October 18, 2017
The BIO Investor Forum finished today after hosting two days of expert-led panel discussions, fireside chats, over 165 company presentations and more than 2,750 individual meetings arranged through BIO One-on-One Partnering — a 26 percent increase over last year. The event was attended by more than 1,000 representatives of private and early stage biotech companies, leading investment firms, research organizations and others who came together to foster the development of new medical treatments and to grow the industry’s pipeline. 
Read More

Hill Leaders Urge Support for Reg System that Supports Ag Innovation
Press Release  •  October 17, 2017
USDA, FDA and EPA must “coordinate with each other and stakeholders” Washington, D.C. (October 17, 2017) – Under the leadership of Reps. Neal Dunn (R-Fla.) and Jimmy Panetta (D-Calif.), 79 Members of the House of Representatives signed on to a letter urging for a “consistent, science-based, risk-proportionate regulatory system” for agricultural biotechnology.
Read More

Congressional Letter to FDA, USDA and EPA on Animal Biotechnology
Agriculture & Environment, Food & Farm Innovation  •  Letters, Testimony & Comments  •  October 17, 2017

BIO's Letter to the Senate Committee on Judiciary Regarding Deficiencies at the USPTO
Letters, Testimony & Comments  •  October 12, 2017
BIO President and CEO James C. Greenwood details deficiencies at the USPTO that are undermining longstanding and carefully-balanced procedures governing market entry and patent dispute resolution under the highly successful Hatch-Waxman Act.
Read More

BIO Comments on FDA Draft Guidance on CMC Postapproval Manufacturing Changes for Specified Biological Products
Letters, Testimony & Comments  •  October 10, 2017
BIO submitted comments on the Food and Drug Administration’s (FDA) draft guidance, Chemistry, Manufacturing, and Controls Postapproval Manufacturing Changes for Specified Biological Products to Be Documented in Annual Reports. BIO appreciates the effort to categorize listed annual reportable changes for biologics based on the associated commensurate risk, along with the annual reportable manufacturing type examples in the draft guidance. However, BIO recommends the final guidance include examples of situations where annual reportable listed changes may be better categorized by applicants as a supplement based on certain specific circumstances. BIO asks for additional clarifications to the draft guidance, including whether this draft guidance will be aligned with the final ICH Q12 guideline.
Read More

BIO Statement on California Governor Brown Signing Drug Price Reporting & Transparency Bill
Press Release  •  October 9, 2017
BIO will continue to oppose legislative efforts, such as SB 17, that harm patient access to needed care by undermining competition, disrupting existing drug product availability, or stifling investment in the innovation ecosystem through misguided government intrusion.
Read More

BIO Congratulates SAB Biotherapeutics on Pharm Groundbreaking
Press Release  •  October 5, 2017
Sioux Falls, S.D. 80-acre biological pharm is first-of-its kind Washington, D.C. (October 5, 2017) – Sioux Falls, S.D.-based SAB Biotherapeutics, Inc. (SAB), celebrated construction of their 80-acre biopharmaceutical production pharm operation with a groundbreaking ceremony today in Lincoln County. 
Read More